Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol, 15 (1997), pp. 2403-2413 Google Scholar 13 MJ Moore, D Goldstein, J Hamm, A Figer, JR Hecht, S Gallinger, et al. Erlotinib plu...
the median and five years survival were 14 months and 16% for bile duct cancer and 11 months and 14% for pancreatic cancer. multivariate analysis identified tumor type (pancreas /bile duct) and lymph node dissemination as independent predictors of mortality. conclusions: one quarter of patients ...